간염 검사용 솔루션 및 진단 시장 : 제품 유형, 검사 유형, 기술, 검사 방법, 용도, 최종 사용자, 간염 유형, 질환 진행 단계별 예측(2026-2032년)

The Hepatitis Test Solution/Diagnosis Market is projected to grow by USD 5.79 billion at a CAGR of 5.72% by 2032.

Executive Introduction to Hepatitis Test Solutions

Viral hepatitis remains one of the most consequential infectious disease burdens for health systems, laboratories, and diagnostic manufacturers. The World Health Organization reported 304 million people living with chronic hepatitis B or C in 2022, with hepatitis-related mortality comparable to major global communicable diseases. This creates sustained demand for hepatitis test solutions spanning screening, confirmatory diagnosis, viral load monitoring, genotyping, point-of-care testing, and laboratory automation.

The hepatitis diagnosis landscape is shaped by public health screening mandates, blood safety requirements, antenatal testing, harm-reduction programs, and growing clinical adoption of nucleic acid testing. High-value sector themes include hepatitis testing, hepatitis diagnosis, HBV testing, HCV testing, liver infection diagnostics, viral hepatitis screening, molecular diagnostics, immunoassay testing, rapid diagnostic testing, and point-of-care hepatitis tests.

Transformative Shifts in the Hepatitis Diagnostics Landscape

The landscape is shifting from episodic, risk-based testing toward broader population screening and integrated care pathways. In the United States, CDC recommendations support universal adult screening for hepatitis B and hepatitis C, while WHO guidance emphasizes expanded diagnosis as a core requirement for viral hepatitis elimination by 2030. These policy changes are increasing demand for scalable serology, rapid diagnostic tests, and high-throughput molecular platforms.

Another major shift is decentralization. Hospitals and reference laboratories remain essential, but community clinics, antenatal programs, prisons, blood banks, and harm-reduction centers increasingly require faster access to reliable hepatitis diagnosis. This favors tests with simplified workflows, lower sample-volume requirements, digital result capture, reflex testing capability, and compatibility with linkage-to-care programs.

Cumulative Impact of Artificial Intelligence on Diagnosis

Artificial intelligence is strengthening hepatitis diagnosis primarily through workflow optimization, patient-risk identification, image-enabled liver assessment, and laboratory decision support. AI can help prioritize high-risk populations, flag abnormal liver enzyme patterns, support reflex testing strategies, and reduce delays between screening and confirmatory diagnosis. These applications align with evidence-based care because final diagnosis still depends on validated immunoassays, molecular tests, and clinician interpretation.

The cumulative impact of AI is expected to be operational rather than substitutive. Laboratories can use predictive analytics to improve test utilization, reduce repeat testing, anticipate reagent needs, and identify care gaps. For diagnostic developers and healthcare providers, AI-enabled platforms may support quality control, automated interpretation, and surveillance analytics, provided systems meet regulatory, privacy, cybersecurity, and clinical validation requirements.

Key Regional Insights Across Major Hepatitis Testing Markets

Asia-Pacific carries a substantial hepatitis B burden, supported by large populations, historical perinatal transmission, and uneven vaccination and birth-dose coverage in several settings. China, India, Japan, South Korea, and Australia show different demand patterns, ranging from high-volume public screening and maternal-child health programs to advanced molecular monitoring and specialist-led liver disease management. North America is characterized by universal screening guidance, strong laboratory capacity, and persistent HCV testing demand linked to injection drug use, aging cohorts, and treatment linkage initiatives.

Europe benefits from mature laboratory infrastructure, surveillance systems, and European Union public health coordination, though diagnosis gaps remain among migrants, underserved communities, incarcerated populations, and people who inject drugs. Latin America is expanding hepatitis testing through blood screening, antenatal care, and public health programs, with Brazil and Mexico anchoring regional diagnostic activity. The Middle East is supported by premarital screening, migrant health programs, centralized healthcare investment, and high-capacity hospital networks, particularly in GCC markets. Africa faces high HBV prevalence in several countries and needs affordable rapid testing, timely birth-dose linkage, safe blood screening, and decentralized molecular access to improve diagnosis and treatment initiation.

Key Group Insights for Hepatitis Testing Demand

ASEAN demand is supported by high population density, expanding universal health coverage, and ongoing HBV prevention programs, with countries prioritizing affordable screening, antenatal testing, and maternal-child health integration. The GCC is more infrastructure-led, with national screening programs, migrant health assessments, medical tourism, and centralized procurement supporting premium diagnostic adoption. The European Union emphasizes surveillance quality, harmonized public health standards, blood safety, and viral hepatitis elimination targets, creating demand for both laboratory automation and outreach testing.

BRICS countries represent a high-volume diagnostic environment because Brazil, Russia, India, China, and South Africa combine sizable populations, varied hepatitis burdens, and expanding domestic diagnostic capabilities. G7 markets drive innovation through regulatory rigor, reimbursement maturity, integrated laboratory networks, and adoption of high-throughput molecular diagnostics. NATO countries overlap heavily with high-income European and North American systems, where military health services, blood safety standards, deployable medical capabilities, and infectious disease readiness reinforce demand for reliable hepatitis testing.

Key Country Insights in Hepatitis Diagnosis

The United States leads in guideline-driven HBV and HCV screening, advanced molecular testing, and large-scale laboratory infrastructure, while Canada emphasizes public health access, Indigenous health priorities, and harm-reduction-linked HCV testing. Mexico and Brazil are important Latin American markets due to population size, blood safety programs, antenatal testing, and expanding public diagnostics. The United Kingdom, Germany, France, Italy, and Spain maintain strong laboratory networks, national health systems, and public health screening capacity, while Russia shows continued need for HBV and HCV diagnosis across a broad geography and diverse care settings.

China and India are central to global hepatitis testing because of their large populations and substantial chronic HBV burden, with rising demand for affordable immunoassays, rapid screening, and molecular confirmation. Japan, Australia, and South Korea represent advanced Asia-Pacific markets with mature screening systems, high-quality laboratories, and strong clinical monitoring for chronic liver disease. Across these countries, progress depends on earlier diagnosis, reflex testing, treatment linkage, digital reporting, and integration of hepatitis screening into routine primary care, antenatal services, blood safety systems, and community outreach.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated, scalable, and cost-efficient hepatitis testing portfolios that cover screening, confirmation, viral load monitoring, genotyping where clinically required, and treatment follow-up. Product strategies should align with WHO elimination goals, universal screening trends, blood bank requirements, antenatal care, occupational health protocols, and outreach programs for high-risk and underserved populations.

Organizations should invest in point-of-care and near-patient testing where access barriers remain high, while maintaining high-throughput platforms for centralized laboratories. Partnerships with public health agencies, payers, non-governmental organizations, and digital health providers can improve linkage to care. Leaders should also strengthen regulatory evidence, quality management, local supply resilience, training programs, and AI-enabled workflow tools that improve laboratory productivity without compromising diagnostic accuracy.

Research Methodology and Data Validation

The research methodology integrates secondary research from globally recognized health authorities, including WHO, CDC, ECDC, national health ministries, regulatory agencies, blood safety programs, and peer-reviewed clinical literature. Interpretation considers disease burden, screening recommendations, test adoption, healthcare infrastructure, reimbursement, procurement models, diagnostic technology trends, and the role of laboratory and point-of-care testing.

The analysis is structured to support executive decision-making across product strategy, regional expansion, competitive positioning, and commercialization. Insights are validated through triangulation of epidemiological evidence, policy direction, laboratory practice patterns, regulatory guidance, and technology adoption indicators, ensuring that conclusions remain data-backed and relevant to the hepatitis test solution and diagnosis landscape.

Conclusion: Strategic Outlook for Hepatitis Diagnostics

The hepatitis test solution landscape is positioned for durable relevance as governments and healthcare systems intensify efforts to close diagnosis gaps. With hundreds of millions of people living with chronic hepatitis B or C and many still undiagnosed, reliable screening and confirmatory testing remain essential to reducing liver cirrhosis, hepatocellular carcinoma, transmission risk, and preventable mortality.

Future leadership will depend on accessible testing, laboratory efficiency, regulatory quality, affordability, and faster linkage to care. Organizations that combine validated immunoassay and molecular diagnostics with decentralized access, digital reporting, and AI-supported workflow intelligence will be best positioned to support global viral hepatitis elimination objectives.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hepatitis Test Solution/Diagnosis Market, by Product Type

• 7.1. Instruments
  • 7.1.1. Bench-Top Instruments
  • 7.1.2. High-Throughput Instruments
• 7.2. Kits & Consumables
  • 7.2.1. Test Kits
  • 7.2.2. Assay Reagents
• 7.3. Software & Services

8. Hepatitis Test Solution/Diagnosis Market, by Test Type

• 8.1. Serological Tests
  • 8.1.1. Antigen Tests
  • 8.1.2. Antibody Tests
• 8.2. Molecular / Nucleic Acid Tests
• 8.3. Rapid Diagnostic Tests (RDTs)
  • 8.3.1. Lateral Flow Assays
  • 8.3.2. Point-of-Care (POC) Kits
• 8.4. Liver Function Tests (Supportive Diagnostics)
  • 8.4.1. ALT / AST Tests
  • 8.4.2. Bilirubin Tests
• 8.5. Genotyping & Viral Load Testing

9. Hepatitis Test Solution/Diagnosis Market, by Technology

• 9.1. Enzyme-Linked Immunosorbent Assay (ELISA)
• 9.2. Chemiluminescent Immunoassay (CLIA)
• 9.3. Polymerase Chain Reaction (PCR)
• 9.4. Isothermal Amplification
• 9.5. Lateral Flow Immunoassay
• 9.6. Sequencing Technologies (NGS)

10. Hepatitis Test Solution/Diagnosis Market, by Mode of Testing

• 10.1. Laboratory-Based Testing
• 10.2. Point-of-Care (POC) Testing
• 10.3. Home-Based / Self-Testing

11. Hepatitis Test Solution/Diagnosis Market, by Application

• 11.1. Screening
• 11.2. Diagnosis / Confirmation
• 11.3. Viral Load Monitoring
• 11.4. Treatment Monitoring & Prognosis
• 11.5. Epidemiological Surveillance

12. Hepatitis Test Solution/Diagnosis Market, by End User

• 12.1. Blood Banks
• 12.2. Diagnostic Laboratories
• 12.3. Home Care Settings
• 12.4. Hospitals & Clinics
• 12.5. Academic & Research Institutes

13. Hepatitis Test Solution/Diagnosis Market, by Hepatitis Type

• 13.1. Hepatitis A (HAV)
• 13.2. Hepatitis B (HBV)
• 13.3. Hepatitis C (HCV)
• 13.4. Hepatitis D (HDV)
• 13.5. Hepatitis E (HEV)

14. Hepatitis Test Solution/Diagnosis Market, by Disease Stage

• 14.1. Acute Infection Testing
• 14.2. Chronic Infection Monitoring
• 14.3. Post-Treatment Monitoring

15. Hepatitis Test Solution/Diagnosis Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Hepatitis Test Solution/Diagnosis Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Hepatitis Test Solution/Diagnosis Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. Abbott Laboratories
• 19.2. ACON Laboratories, Inc.
• 19.3. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
• 19.4. Bio-Rad Laboratories, Inc.
• 19.5. BioCheck, Inc.
• 19.6. bioMerieux SA
• 19.7. CTK Biotech, Inc.
• 19.8. Danaher Corporation
• 19.9. DIALAB GmbH
• 19.10. DiaSorin S.p.A.
• 19.11. Getein Biotech, Inc.
• 19.12. Guangzhou Wondfo Biotech Co., Ltd.
• 19.13. H.U. Group Holdings, Inc.
• 19.14. Hangzhou AllTest Biotech Co., Ltd.
• 19.15. Hologic, Inc.
• 19.16. HUMAN Gesellschaft fur Biochemica und Diagnostica mbH
• 19.17. InTec PRODUCTS, INC.
• 19.18. J. Mitra & Co. Pvt. Ltd.
• 19.19. Jiangsu BioPerfectus Technologies Co., Ltd.
• 19.20. Maccura Biotechnology Co., Ltd.
• 19.21. Meril Life Sciences Pvt. Ltd.
• 19.22. OraSure Technologies, Inc.
• 19.23. Premier Medical Corporation Private Limited
• 19.24. QIAGEN N.V.
• 19.25. QuidelOrtho Corporation
• 19.26. Revvity, Inc.
• 19.27. Roche Holding Ltd
• 19.28. Sansure Biotech Inc.
• 19.29. Seegene Inc.
• 19.30. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 19.31. Shenzhen New Industries Biomedical Engineering Co., Ltd.
• 19.32. Siemens Healthineers AG
• 19.33. Sysmex Corporation
• 19.34. Transasia Bio-Medicals Ltd.
• 19.35. Tulip Diagnostics (P) Ltd.